D. E. Shaw & Co. Inc. Has $5.48 Million Stock Position in OraSure Technologies, Inc. (NASDAQ:OSUR)

D. E. Shaw & Co. Inc. increased its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 180.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,517,541 shares of the medical instruments supplier's stock after buying an additional 976,475 shares during the quarter. D. E. Shaw & Co. Inc. owned 2.03% of OraSure Technologies worth $5,478,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Franklin Resources Inc. increased its position in shares of OraSure Technologies by 28.5% during the 3rd quarter. Franklin Resources Inc. now owns 269,269 shares of the medical instruments supplier's stock worth $1,091,000 after purchasing an additional 59,723 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of OraSure Technologies by 5.8% during the third quarter. JPMorgan Chase & Co. now owns 847,933 shares of the medical instruments supplier's stock valued at $3,621,000 after acquiring an additional 46,216 shares during the period. SG Americas Securities LLC acquired a new stake in shares of OraSure Technologies during the 4th quarter worth approximately $205,000. Exchange Traded Concepts LLC bought a new stake in shares of OraSure Technologies during the fourth quarter worth approximately $287,000. Finally, Empowered Funds LLC lifted its holdings in OraSure Technologies by 5.1% in the fourth quarter. Empowered Funds LLC now owns 377,906 shares of the medical instruments supplier's stock valued at $1,364,000 after buying an additional 18,487 shares during the period. Institutional investors and hedge funds own 93.50% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Evercore ISI restated an "in-line" rating and set a $3.00 target price on shares of OraSure Technologies in a research report on Monday. Wall Street Zen raised shares of OraSure Technologies from a "sell" rating to a "hold" rating in a research note on Saturday, May 17th.

Insider Transactions at OraSure Technologies

In other OraSure Technologies news, CFO Kenneth J. Mcgrath acquired 64,000 shares of OraSure Technologies stock in a transaction dated Thursday, February 27th. The stock was bought at an average cost of $3.15 per share, for a total transaction of $201,600.00. Following the purchase, the chief financial officer now directly owns 371,013 shares in the company, valued at approximately $1,168,690.95. This represents a 20.85% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director John P. Kenny acquired 47,659 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was bought at an average price of $3.17 per share, with a total value of $151,079.03. Following the acquisition, the director now directly owns 70,915 shares in the company, valued at $224,800.55. This represents a 204.93% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 190,284 shares of company stock valued at $600,348 in the last ninety days. 3.90% of the stock is currently owned by corporate insiders.

OraSure Technologies Trading Up 1.4%

Shares of OSUR stock traded up $0.04 on Thursday, hitting $2.59. 154,773 shares of the stock were exchanged, compared to its average volume of 855,817. The firm has a market capitalization of $193.36 million, a P/E ratio of 17.17 and a beta of 0.42. OraSure Technologies, Inc. has a fifty-two week low of $2.36 and a fifty-two week high of $5.08. The business has a 50-day moving average of $3.03 and a 200 day moving average of $3.54.

OraSure Technologies declared that its board has authorized a stock repurchase plan on Monday, March 24th that permits the company to repurchase $40.00 million in shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 15.6% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's management believes its shares are undervalued.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.